Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Sorting protein VPS33B regulates exosomal autocrine signaling to mediate hematopoiesis and leukemogenesis
Hao Gu, … , Guo-Qiang Chen, Junke Zheng
Hao Gu, … , Guo-Qiang Chen, Junke Zheng
Published October 31, 2016
Citation Information: J Clin Invest. 2016;126(12):4537-4553. https://doi.org/10.1172/JCI87105.
View: Text | PDF | Retraction
Research Article Hematology

Sorting protein VPS33B regulates exosomal autocrine signaling to mediate hematopoiesis and leukemogenesis

  • Text
  • PDF
Abstract

Certain secretory proteins are known to be critical for maintaining the stemness of stem cells through autocrine signaling. However, the processes underlying the biogenesis, maturation, and secretion of these proteins remain largely unknown. Here we demonstrate that many secretory proteins produced by hematopoietic stem cells (HSCs) undergo exosomal maturation and release that is controlled by vacuolar protein sorting protein 33b (VPS33B). Deletion of VPS33B in either mouse or human HSCs resulted in impaired exosome maturation and secretion as well as loss of stemness. Additionally, VPS33B deficiency led to a dramatic delay in leukemogenesis. Exosomes purified from either conditioned medium or human plasma could partially rescue the defects of HSCs and leukemia-initiating cells (LICs). VPS33B co-existed in exosomes with GDI2, VPS16B, FLOT1, and other known exosome markers. Mechanistically, VPS33B interacted with the GDI2/RAB11A/RAB27A pathway to regulate the trafficking of secretory proteins as exosomes. These findings reveal an essential role for VPS33B in exosome pathways in HSCs and LICs. Moreover, they shed light on the understanding of vesicle trafficking in other stem cells and on the development of improved strategies for cancer treatment.

Authors

Hao Gu, Chiqi Chen, Xiaoxin Hao, Conghui Wang, Xiaocui Zhang, Zhen Li, Hongfang Shao, Hongxiang Zeng, Zhuo Yu, Li Xie, Fangzhen Xia, Feifei Zhang, Xiaoye Liu, Yaping Zhang, Haishan Jiang, Jun Zhu, Jiangbo Wan, Chun Wang, Wei Weng, Jingjing Xie, Minfang Tao, Cheng Cheng Zhang, Junling Liu, Guo-Qiang Chen, Junke Zheng

×

Figure 3

VPS33B maintains HSC functions.

Options: View larger image (or click on image) Download as PowerPoint
VPS33B maintains HSC functions.
(A) WT and VPS33B-null BM CD45.2 cells a...
(A) WT and VPS33B-null BM CD45.2 cells along with CD45.1 competitor cells were injected into lethally irradiated CD45.1 recipient mice (n = 5; **P < 0.01, ***P < 0.001 using Student’s t test). Repopulation was analyzed at 3, 8, and 16 weeks after transplantation. (B) Multilineage contribution of donor cells in the primary recipients at 16 weeks post-transplantation (n = 5; *P < 0.05 using Student’s t test). (C) Secondary transplantation was performed with FACS-purified donor CD45.2 BM cells from WT and VPS33B-null primary recipients. Repopulation was analyzed at 4, 8, and 16 weeks after transplantation (n = 5; **P < 0.01, ***P < 0.001 using Student’s t test). (D) Multilineage contribution of donor cells in secondary recipients 16 weeks after transplantation (n = 5; *P < 0.05 using Student’s t test). (E) Vps33bwt/wt Scl-Cre-ER (VPS33B+/+) and Vps33bfl/fl Scl-Cre-ER (VPS33B–/–) mice were intraperitoneally administered 150 mg/kg 5-FU weekly for 3 times (arrows), and the survival rates were analyzed (n = 7; *P < 0.05 using log-rank test). (F) Vps33bfl/fl Scl-Cre-ER+ BM cells or Vps33bwt/wt Scl-Cre-ER+ BM cells (3 × 105 cells) along with competitor cells were transplanted into lethally irradiated CD45.1 recipient mice, followed by the treatment with tamoxifen 8 weeks after transplantation and analysis for repopulation from 2 to 24 weeks after treatment. Vps33b deletion (arrow) was shown after 2-week treatment (n = 5; **P < 0.01, ***P < 0.001 using Student’s t test). (G) Multilineage contribution of donor cells 24 weeks after transplantation (n = 5; *P < 0.05 using Student’s t test). (H and I) WT and VPS33B-null LT-HSCs were analyzed for cell cycle stage by staining with Hoechst33342/Pyronin Y (H), and the frequencies of the G0, G1, and S-G2-M fractions were quantified (n = 3; *P < 0.05, ***P < 0.001 using Student’s t test) (I). (J) Apoptosis was measured in LT-HSCs from VPS33B+/+ and VPS33B–/– mice by using annexin V/7-AAD staining (n = 5; ***P < 0.001 using Student’s t test). (K) Representative images of LT-HSCs from VPS33B+/+ and VPS33B–/– mice 10 days after culturing in basic medium (SCF+TPO) (n = 6). (L–N) Cell numbers (L), percentages of LSK cells (M), and percentages of apoptotic cells (N) were evaluated in cultured WT and VPS33B-null LT-HSCs (n = 6; *P < 0.05, **P < 0.01, ***P < 0.001 using Student’s t test). Experiments were conducted 3 to 5 times for validation.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts